Oppenheimer Downgrades Dyne Therapeutics to Perform, Lowers Price Target to $15
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsDowngradesPrice Target
Oppenheimer analyst Kostas Biliouris downgrades Dyne Therapeutics (NASDAQ:DYN) from Outperform to Perform and lowers the price target from $40 to $15.
Oppenheimer analyst Kostas Biliouris downgrades Dyne Therapeutics (NASDAQ:DYN) from Outperform to Perform and lowers the price target from $40 to $15.